Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer

Post time 2022-7-2 12:14:15

journal：Clinical Pharmacology & Therapeutics

Authors：Laura Molenaar‐Kuijsten; C. Louwrens Braal; Stefanie L. Groenland; Niels Vries; Hilde Rosing; Jos H. Beijnen; Stijn L.W. Koolen; Annelie J.E. Vulink; Marloes G.J. Dongen; Ron H.J. Mathijssen; Alwin D.R. Huitema; Neeltje Steeghs;

Published date：2022-2-

DOI：10.1002/cpt.2455

Article link：http://dx.doi.org/10.1002/cpt.2455

Article Source：Wiley。

Remark：

Post time 2022-7-2 12:14:16

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2022-7-2 14:21:09

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today